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Open access under CC BYa b s t r a c tFollowing the initial description of endothelium-dependent vasoconstriction in the early 1980s, it has been
exactly 25 years since efforts to identify the sequence of the endothelin gene and peptide began in May
1987, work which resulted in a landmark paper submitted to Nature in December 1987 and published on
March 31, 1988. The paper opened an entirely new ﬁeld of research, followed by the inception of the Inter-
national Conferences of Endothelin, the ﬁrst of which was organized by Sir John Vane as Chair and held as
the “First William Harvey Workshop on Endothelin” in London, UK, in December of 1988. Endothelin receptor
antagonism has now been ﬁrmly established for more than a decade as a new, orally active drug treatment
for patients with pulmonary arterial hypertension. Since the discovery of endothelin, on average 1,000 papers
per year have been published with more than 25,000 papers available today, many of them published in the
conferences' Proceedings. The present issue of Life Sciences, Endothelin XII, represents a collection of papers
of original research and invited lectures presented at the Twelfth International Conference on Endothelin
held in Cambridge, UK, in September 2011.
© 2012 Elsevier Inc. Open access under CC BY-NC-ND license.Following the initial description of endothelium-dependent va-
soconstriction in the early 1980s (De Mey and Vanhoutte, 1982;
Barton, 2011), it has been exactly 25 years since efforts to identify
the sequence of the endothelin gene and peptide began in May
1987 (Masaki, 1998), work which resulted in a landmark paper sub-
mitted to Nature in December 1987 and published on March 31,
1988 (Yanagisawa et al., 1988). The paper opened an entirely new
ﬁeld of research, followed by the inception of the International Con-
ferences of Endothelin, the ﬁrst of which was organized by Sir John
Vane as Chair and held as the “First William Harvey Workshop on
Endothelin” in London, UK, in December of 1988 (Barton and
Davenport, 2012).
Endothelin receptor antagonism has now been ﬁrmly established
for more than a decade as a new, orally active drug treatment for pa-
tients with pulmonary arterial hypertension (Rubin, 2012). Since theine, University of Zürich, LTK
itzerland. Tel.: +41 77 439
-NC-ND license.discovery of endothelin, on average 1,000 papers per year have been
published (Barton and Yanagisawa, 2008) with more than 25,000 pa-
pers available today, many of them published in the conferences'
Proceedings (1989, 1991, 1993, 1995, 1998, 2000, 2002, 2004, 2006,
2008, 2010, 2012). The present issue of Life Sciences, Endothelin XII,
represents a collection of papers of original research and invited lec-
tures presented at the Twelfth International Conference on Endothelin
held in Cambridge, UK, in September 2011 (Barton and Davenport,
2012). Each manuscript – either full papers of original research articles
or review articles – was rigorously peer-reviewed by at least three in-
ternational experts mainly recruited from the Endothelin XII Editorial
Board and many of these manuscripts went through several revisions
prior to being accepted.
Endothelin XII in its new format of the Endothelin Conference
Proceedings is the result of some fortunate coincidences and
has allowed us to provide readers with a number of “ﬁrsts” with re-
gard to scientiﬁc publishing in general and with regard to publish-
ing papers from the International Conferences on Endothelin in
particular.
First,wewere fortunate towin theworld's largest scientiﬁc publisher,
Elsevier, with their highly regarded, multidisciplinary journal Life
Sciences as the new medium for the publication of the Endothelin Con-
ference Proceedings.
450 M. Barton et al. / Life Sciences 91 (2012) 449–451Second, given the rapid development of sharing information via the
internet and by using videomessaging –which is now regularly used by
news agencies, television stations, and even daily newspapers – it is ob-
vious that providing video information is highly useful for also deliver-
ing scientiﬁc information. In the planning stages for the ET-12
conference and publication of the Endothelin XII Proceedings the idea
was born to provide high-deﬁnition video recordings of ET-12 confer-
ence presentations and lectures to the public. The Endothelin XII Pro-
ceedings are the ﬁrst in scientiﬁc publishing to combine published
Proceedings papers online with the corresponding conference presen-
tation as video together with the full online text on the publisher's
website. This will allow readers not only to virtually “meet” the authors
of the paper presented, but also to obtain additional information (in-
cluding presentation slides) from original presentations given at the
conference.
Third, in collaboration and support with Elsevier, we are happy and
proud to announce that all articles published in the Endothelin XII Pro-
ceedings are publishedwithOpenAccess™ to ensure global distribution
and access for the scientiﬁc community from any computer in the
world.
Fourth, the Proceedings for the ﬁrst time contain a number of
up-to-date, in-depth review articles written by authorities in the
ﬁeld who presented lectures at the ET-12 conference, with most of
them also available with the corresponding video recording of the
author's lecture on the article website.
And ﬁfth, with the support of Elsevier we have launched the
“Endothelin Conferences Best Presentation Awards” (Barton and
Pollock, 2012) which includes a subscription to Life Sciences and an
invitation to the awardees by the Guest Editor to submit a review ar-
ticle on their work for publication in the Journal which has been real-Matthias Barton, M.D. Masashi Yanagisawa, M.D., Ph.D. Paul M.Vanhoutte, M
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Tokyoized the ﬁrst time in the Endothelin XII Proceedings (von Brandenstein
et al., 2012).
We are conﬁdent that all of the above “ﬁrsts” will prove to be
successful now and in the future in helping to disseminate knowledge
in the ﬁeld of endothelin science and tomotivate young researchers to
embark in this area of research. In addition, we have also succeeded to
established the basis for a permanent, open access knowledge data-
base with up-do-date media access from previous and for future
endothelin conferences (Endothelin Conferences website).
We are indebted to all members of the Life Sciences Endothelin
Conferences Special Editorial Board and manuscript reviewers who did a
tremendous job by providing their expertise and reviewing a large num-
ber manuscripts in record time, and also to Dr. Anthony P. Davenport,
ET-12 Co-Chair and Guest Associate Editor, and to Dr. David M. Pollock,
Guest Associate Editor, who has handled several manuscripts of the
Endothelin XII Proceedings. We also express our gratitude to Dr. Irene
Kanter-Schliffke of Elsevier as the publisher of Life Sciences, for her out-
standing and most professional support and that of her team without
whom the new ideas realized in this volume would not have been possi-
ble. Our sincere thanks also go to Karen Schlaegel as Head of Meetings
with the BPS for an outstanding job in organizing the ET-12 Conference.
It is our goal that through Open Access™ global availability the papers
published in the Endothelin XII Proceedings will receive the attention in
the scientiﬁc community that they deserve and that the newglobal access
will further improve communication and advancement in the ﬁeld of
endothelin research.
We hope that you will enjoy this very Special Issue of the Proceed-
ings of the Twelfth International Conference on Endothelin.
May 2012.D., Ph.D. Tomoh Masaki, M.D. Ph.D.
ditor Honorary Guest Editor Appendix A. Supplementary data
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.lfs.2012.07.016.References
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